Charles F. von Gunten, MD, PhD, of OhioHealth Kobacker House discusses the ROMANA 1 and 2 trials on cachexia in NSCLC and a study on olanzapine vs fosaprepitant for the prevention of nausea and vomiting (Abstracts 9500 and 9502).
Leonard Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.
Patrick Schöffski, MD, of the University Hospital Leuven, discusses a phase III study in which he and his colleagues found, for the first time in soft-tissue sarcomas, a significant overall survival benefit of a single agent compared to a standard treatment (Abstract LBA10502).
James O. Armitage, MD, of the University of Nebraska Medical Center, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss oncology from an international point of view.
Robert W. Carlson, MD, of the National Comprehensive Cancer Network, and Richard G. Margolese, MD, of McGill University, discuss the improvement in breast cancer–free interval with anastrozole vs tamoxifen in patients with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract LBA500).
